

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/039563 A1

(51) International Patent Classification:

C07D 333/24 (2006.01) A61P 25/28 (2006.01)
A61K 31/381 (2006.01) A61P 29/00 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/KR2021/011143

(22) International Filing Date:

20 August 2021 (20.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2020-0105545 21 August 2020 (21.08.2020) KR

(71) Applicants: KANAPH THERAPEUTICS INC.

[KR/KR]; 5th floor, 3, Itaewon-ro 55ga-gil, Yongsan-gu, Seoul 04348 (KR). KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY [KR/KR]; 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 (KR).

(72) Inventors: SHIN, Young Sook; #211-1801, 165, Siheung-daero, Geumcheon-gu, Seoul 08637 (KR). LIM, Sang Kyun; #1321, 156, Mapo-daero, Mapo-gu, Seoul 04211 (KR). LEE, Yeri; #301, 23, Wiryeseong-daero 6-gil, Songpa-gu, Seoul 05629 (KR). KIM, Donggeon; #301, 23, Wiryeseong-daero 6-gil, Songpa-gu, Seoul 05629 (KR). HAN, Soo Bong; 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 (KR). YUN, Chang Soo; 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 (KR). KIM, Hyun Jin; 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 (KR). LEE, Joo Youn; 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 (KR). LEE, Hyuk; 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 (KR). SEONG, Sikwang; 141, Gajeong-ro, Yuseong-gu, Daejeon 34114 (KR).

(74) Agent: RYU, Jong Woo et al.; Sunjung IP Law Firm, 4th floor, Myungji Building, 13 Tehcran-ro 69-gil, Gangnam-gu, Seoul 06160 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF

(57) Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E₂ receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.

WO 2022/039563 A1